Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (6)

ProteinN (2)

NSP16 (1)

NSP5 (1)

ORF1ab (1)


SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 67
    records per page

    Predicting the severity of disease progression in COVID-19 MESHD at the individual and population level: A mathematical model

    Authors: Narendra Chirmule; Pradio Nair; Bela Desai; Ravindra Khare; Vivek R Nerurkar; Amitabh Gaur

    doi:10.1101/2021.04.01.21254804 Date: 2021-04-07 Source: medRxiv

    The impact of COVID-19 MESHD disease on health and economy has been global, and the magnitude of devastation is unparalleled in modern history. Any potential course of action to manage this complex disease requires the systematic and efficient analysis of data that can delineate the underlying pathogenesis. We have developed a mathematical model of disease progression to predict the clinical outcome, utilizing a set of causal factors known to contribute to COVID-19 MESHD pathology such as age, comorbidities, and certain viral and immunological parameters. Viral load and selected indicators of a dysfunctional MESHD immune response, such as cytokines IL-6 HGNC and IFNab; which contribute to the cytokine storm and fever MESHD, parameters of inflammation MESHD d-dimer and ferritin, aberrations in lymphocyte number, lymphopenia MESHD, and neutralizing antibodies were included for the analysis. The model provides a framework to unravel the multi-factorial complexities of the immune response manifested in SARS-CoV-2 infected MESHD individuals. Further, this model can be valuable to predict clinical outcome at an individual level and to develop strategies for allocating appropriate resources to mitigate severe cases at a population level.

    Co-infection of SARS-CoV-2 MESHD with influenza among COVID-19 MESHD cases: A-meta analysis

    Authors: Reza Alizadeh-Navaei; Monireh Golpur; Reza Valadan; Masoumeh Rezaei; Moammadreza Haghshenas; Tahoora Mousavi

    doi:10.21203/ Date: 2021-03-07 Source: ResearchSquare

    Background The severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), that causes coronavirus disease 2019 MESHD ( COVID-19 MESHD) is a public health problem and may have co-infection MESHD with other pathogens such as influenza virus.Objective This study aims to assess the co-infection of SARS-CoV-2 MESHD with influenza among COVID-19 MESHD cases.Material and methods The all relevant studies were collected from international databases. For improving the quality of the present literature, the all studies were evaluated by two reviewers in order to confirm all of the studies have inclusion criteria. Finally, all articles with sufficient quality scores were included in meta-analysis. Assessment of heterogeneity among the studies of primary studies was performed using the statistic chi‐squared test (Cochran's Q) and I2 index. In this results, random or fixed effect model were used for determination of heterogeneity test. All statistical analyses were performed using Comprehensive Meta-Analysis (CMA), V.2 software.Results This meta- analysis included 9 primary studies investigating the co-infection of SARS-CoV-2 MESHD with influenza among COVID-19 MESHD cases. Pooled prevalence (95% confidence interval) of co-infection MESHD is shown that the prevalence of influenza A is higher than influenza B. 2.3(0.5-9.3) vs 0.1 (0.4-3.3). Using the fixed effect model the frequency of fever MESHD was (80.6% [95% CI 76.1–84.40, p < 0.153]) and it is shown that fever MESHD is the most prevalent symptom in patients.Conclusion Patients admitted to hospital with COVID-19 MESHD also infected with influenza virus. Thus, the current research provides a better understanding about the control and treatment of co-infection MESHD with SARS-CoV-2 and the influenza virus.

    Delayed rise of oral fluid antibodies, elevated BMI, and absence of early fever MESHD correlate with longer time to SARS-CoV-2 RNA clearance in an longitudinally sampled cohort of COVID-19 MESHD outpatients

    Authors: Annukka A. R. Antar; Tong Yu; Nora Pisnic; Razvan Azamfirei; Jeffrey A Tornheim; Diane M. Brown; Kate Kruczynski; Justin P. Hardick; Thelio Sewell; Minyoung Jang; Taylor Church; Samantha N. Walch; Carolyn Reuland; Vismaya S. Bachu; Kirsten Littlefield; Han-Sol Park; Rebecca L. Ursin; Abhinaya Ganesan; Oyinkansola Kusemiju; Brittany Barnaba; Curtisha Charles; Michelle Prizzi; Jaylynn R. Johnstone; Christine Payton; Weiwei Dai; Joelle Fuchs; Guido Massaccesi; Derek T. Armstrong; Jennifer L. Townsend; Sara C. Keller; Zoe O Demko; Chen Hu; Mei-Cheng Wang; Lauren M. Sauer; Heba H. Mostafa; Jeanne C. Keruly; Shruti H. Mehta; Sabra L. Klein; Andrea L. Cox; Andrew Pekosz; Christopher D. Heaney; David L. Thomas; Paul W. Blair; Yukari C. Manabe

    doi:10.1101/2021.03.02.21252420 Date: 2021-03-03 Source: medRxiv

    Background Viral and immune kinetics in mild to moderate COVID-19 MESHD are understudied because of challenges inherent in longitudinal sampling of people who are infectious to others, feeling ill, yet are not hospitalized. In particular, sustained molecular detection of SARS-CoV-2 RNA in the upper respiratory tract (URT) in mild to moderate COVID-19 MESHD is common and confounds surveillance efforts in the community. We sought to identify host and immune determinants of prolonged SARS-CoV-2 RNA detection via longitudinal viral RNA, virus culture, and plasma and oral fluid antibody sampling in a prospective observational cohort study of adult outpatients with COVID-19 MESHD. Methods and Findings Samples from 95 non-hospitalized participants [≥] 30 years old with recent COVID-19 MESHD diagnosis and known symptom onset date were analyzed. Participants self-collected mid-turbinate nasal, oropharyngeal (OP), and gingival crevicular fluid (oral fluid) samples at home and in a research clinic a median of 6 times over 1-3 months. SARS-CoV-2 RT-PCR performed on 507 URT samples revealed a median time to viral RNA clearance of the URT of 33.5 days. Sixteen nasal-OP samples collected 2-11 days post-symptom onset were virus culture positive out of 183 RT-PCR positive samples tested. All participants but one with positive virus culture were negative for concomitant oral fluid anti- SARS-CoV-2 spike PROTEIN-receptor binding domain (S-RBD) antibodies. The kinetics of oral fluid anti-SARS-Cov-2 antibodies were measured using a multiplex immunoassay. The mean time to first detection of oral fluid anti-SARS-CoV-2 antibodies was 8-13 days post-symptom onset. Associations of symptoms, host demographics, comorbidities, and immune kinetics with time to SARS-CoV-2 RNA clearance were estimated using Cox proportional hazards models. A longer time to first detection of oral fluid anti- SARS-CoV-2 S MESHD antibodies was independently associated with a longer time to SARS-CoV-2 viral RNA clearance (aHR 0.96, 95% CI 0.92-0.99, p=0.020). BMI [≥] 25kg/m2 was also independently associated with a longer time to viral RNA clearance (aHR 0.37, 95% CI 0.18-0.78, p=0.009). Fever MESHD reported as one of first three COVID-19 MESHD symptoms was associated with shorter time to viral RNA clearance (aHR 2.06, 95% CI 1.02-4.18, p=0.044). Plasma titers of neutralizing antibodies, SARS-CoV-2 spike PROTEIN SARS-CoV-2 spike MESHD (S) antibodies, and S-receptor binding domain (S-RBD) antibodies were obtained at 1-4 months post-symptom onset. BMI was positively correlated with post-acute plasma SARS-CoV-2-specific neutralizing antibody titer and anti-S-RBD antibody titer. Conclusions In an intensively sampled cohort of 95 adult outpatients with COVID-19 MESHD, we demonstrate that longer time to first detection of oral fluid SARS-CoV-2-specific antibodies, elevated BMI, and absence of early fever MESHD are independently associated with longer time to viral RNA clearance. This work provides insights into the host and immune factors most important for viral clearance in mild to moderate COVID-19 MESHD.

    A longitudinal study of healthcare workers' surveillance during the ongoing COVID-19 MESHD Epidemics in Italy: is SARS-CoV-2 still a threat for the Health-care System?

    Authors: Francesco Barbaro; Foscarina Della Rocca; Andrea Padoan; Ada Aita; Cianci Vito; Daniela Basso; Annamaria Cattelan; Daniele Donato; Mario Plebani; Luigi Dall'Olmo

    doi:10.1101/2021.02.23.21249481 Date: 2021-02-24 Source: medRxiv

    Objectives: In spring 2020, Northern Italy was the first area outside China to be involved in the SARS-CoV-2 pandemic. This observational study depicts SARS-CoV-2 prevalence and serological curves among first-line healthcare workers (HCWs) at Padua University Hospital (PdUH), North-East Italy. Method: 344 HCWs, working at the PdUH Emergency Department and Infectious Disease MESHD Unit, underwent a SARS-CoV-2 RNA nasopharyngeal swab with paired IgM and IgG antibody detection for 4 consecutive weeks. At every session, a questionnaire recorded symptoms, signs and recent contacts with SARS-CoV-2 patients. Positive cases were followed up for 5 months. Results: Twenty-seven HCWs (7.84%) had positive serology (Abs) with 12 positive swabs during the study period. Two additional HCWs were positive by swab but without Abs. Fourteen cases (4%) had SARS-CoV-2 infection MESHD before the beginning of the study. An HCW with autoimmune disease MESHD showed false Ab results. 46% of individuals with Abs reported no symptoms, in accordance with previous population studies. Fever MESHD, nasal congestion, diarrhoea MESHD and contacts with SARS-CoV-2 individuals correlated to SARS-CoV-2 infection MESHD. 96% of Abs+ cases showed persistent positive antibodies 5 months later and none was re-infected. Discussion: Correct use of PPEs and separate paths for positive/negative patients in the hospital can result in a low percentage of SARS-CoV-2 infections MESHD among HCWs, even in high risk settings. Frequent testing for SARS-CoV-2 with nasopharyngeal swabs is worthwhile, irrespective of HCWs' symptoms, due to the lack of specificity together with the high percentage of asymptomatic cases. Further studies are needed to elucidate the neutralizing effect of SARS-CoV-2 antibodies.

    An update of coronavirus disease 2019 MESHD ( COVID-19 MESHD): an essential brief for clinicians

    Authors: Afshin Zare; Seyyede Fateme Sadati-Seyyed-Mahalle; Amirhossein Mokhtari; Nima Pakdel; Zeinab Hamidi; Sahar Almasi-Turk; Neda Baghban; Arezoo Khoradmehr; Iraj Nabipour; Mohammad Amin Behzadi; Amin Tamadon

    id:10.20944/preprints202102.0530.v1 Date: 2021-02-23 Source:

    During 2019, the number of patients suffering from cough, fever MESHD and reduction of WBC’s count increased. At the beginning, this mysterious illness was called “ fever MESHD with unknown origin”. At the present time, the cause of this pneumonia MESHD is known as the 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome MESHD corona virus 2 (SARS-CoV-2). The SARS-CoV-2 is one member of great family of coronaviruses. Coronaviruses can cause different kind of illnesses including respiratory, enteric, hepatic, and neurological diseases MESHD in animals like cat and bat. Coronaviruses are enveloped positive-stranded RNA viruses. The SARS-CoV-2 has some particular structures for binding to host cells, reproducing itself in cells and damaging human cells. The SARS-CoV-2 can bind angiotensin-converting enzyme 2 HGNC ( ACE‐2 HGNC) receptors and cause various difficulties for human. The SARS-CoV-2 can cause either not-serious issues like fever MESHD and cough MESHD or serious concerns such as multi-organ failure MESHD. Source(s) of SARS-CoV-2 is under debate. Malayan pangolin and bat are the most suspicious candidate for being sources of the SARS-CoV-2. The SARS-CoV-2 can be transmitted by various ways such as transmitting from infected human to healthy human and can make severe pneumonia MESHD, which can lead to death. The SARS-CoV-2 can infect different kind of people with different ages, races, and social and economic levels. The SARS‐CoV‐2 infection MESHD can cause various sorts of clinical manifestations like cough and fever MESHD and intensity of signs and symptoms depends on sufferer conditions. Clinicians use all of available documents and tests like laboratory, histopathological and radiological findings for diagnosing new cases and curing patients with high accuracy. At the present time, there is no particular way for treating SARS-CoV-2 infection MESHD; neither antiviral drugs nor palliative agents. It seems that the best way for standing against the SARS-CoV-2 infection MESHD is preventing from it by social distancing and vaccination. This review tries to prepare an essential brief update about SARS-CoV-2 infection MESHD for clinicians.

    An Unusual Presentation of Pyelonephritis MESHD: Is it COVID-19 MESHD Related?

    Authors: Liseanne van 't Hof; Lucy Pellikaan; Darius Soonawala; Hossain Roshani

    doi:10.21203/ Date: 2021-02-07 Source: ResearchSquare

    IntroductionIn severe cases of COVID-19 MESHD, late complications such as coagulopathy MESHD and organ injury are increasingly described. In milder cases of the disease, the exact time frame and causal path of late onset complications has not yet been determined. Although direct and indirect renal injury MESHD by SARS-CoV-2 has been confirmed, hemorrhagic renal infection MESHD or coagulative problems in the urinary tract have not yet been described.Case PresentationThis case report describes a 35-year-old female without relevant medical history who, five days after having recovered from an infection with SARS-CoV-2, had an unusual course of acute pyelonephritis of the right kidney MESHD and persistent fever MESHD under targeted antibiotic treatment. A hemorrhagic ureteral obstruction MESHD and severe swollen renal parenchyma preceded the onset of fever MESHD and was related to the developing pyelonephritis MESHD. Sudden thrombotic vascular occlusion MESHD in the right eye appeared during admission. Symmetrical paresthesia in de limbs in combination of severe lower back pain MESHD and gastro-intestinal manifestation was documented and not been explained despite of intensive investigation.ConclusionWe present the unusual combination of culture confirmed bacterial hemorrhagic pyelonephritis MESHD with a blood clot in the proximal right ureter, complicated by a retinal venous thrombosis MESHD, in a patient who had recovered from SARS-CoV-2-infection MESHD five days before presentation. The case is suspect of a COVID-19 MESHD related etiology. 

    COVID-19 MESHD Associated Pancreatitis MESHD: A Review of 66 Cases

    Authors: Zahra Rahimian; Ali Ardekani; Afrooz Feili; Kamran Bagheri Lankarani

    doi:10.21203/ Date: 2021-01-25 Source: ResearchSquare

    Background: Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has shown itself with different clinical manifestations. Besides respiratory distress, cough, and fever MESHD, which were the most common symptoms, pancreatitis MESHD has been reported as a rare presentation of this disease, but the knowledge on this association and its pathogenesis is sparse. Methods: Four databases, including Pub Med, Scopus, Web of Science, and Google Scholar, were searched for the association of pancreatitis MESHD and SARS-CoV- 2 infection MESHD, and 29 relevant articles were extracted and reviewed. Results: We reviewed 29 studies provided 66 cases developed acute pancreatitis MESHD while they were infected with SARS-CoV-2. The mean age of patients was 49.94 ± 16.96. The female to male ratio was 1.06 (33 to 31). In 44% of cases, acute pancreatitis MESHD developed as the primary presentation of Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) and 9% of reported cases, expired.Conclusions: During this pandemic, SARS-CoV-2 should be considered in the differential diagnosis of the patients presenting with acute pancreatitis MESHD. Although pancreatitis MESHD will respond to standard care, these patients need isolation and observation for later development of respiratory symptoms. 

    Neonatal COVID-19 MESHD in French Guiana, a Case-Control study.

    Authors: Narcisse Elenga; Wandji Marie-Josephine; Julie Siban; Mathieu Nacher; Magalie Demar

    doi:10.21203/ Date: 2021-01-14 Source: ResearchSquare

    BackgroundThis study aims to assess the risk of transmission of Severe Acute Respiratory Syndrome Coronavirus 2 MESHD ( SARS COV-2 MESHD) to newborns in the context of breastfeeding practice as part of routine care.MethodsIn this prospective study, we identified neonates born between May 14th and August 31st, 2020, to mothers who tested positive for SARS-CoV-2 at the time of delivery. From the cohort of 974 deliveries, we performed a nested case-control study. ResultsDuring the study period, 133 (13.7%) were positive by RT‐PCR for SARS‐CoV‐2. Among the 35 pregnant women with symptomatic COVID-19 MESHD (26.3%), cough MESHD was the most common symptom, occurring in half of the cases. Among them, 3 developed fever MESHD as other symptoms during hospitalization and 4 have progressed to critical pneumonia MESHD requiring transfer to intensive care unit. Among the neonates born from mothers with positive RT‐PCR for SARS‐CoV‐2, 32 were tested for SARS-COV-2 at 48 hours-7 days. Of them, 3 asymptomatic neonates tested positive. There were no significant differences in fetal distress, meconium-stained amniotic fluid, preterm birth, and neonatal asphyxia MESHD between the two groups Most infants were breastfed at birth, regardless of their mothers' COVID-19 MESHD status. In COVID-19 MESHD-positive pregnant women admitted to intensive care unit, the proportion of preterm births ( OR=12.5 [1.7-90.5]), fetal death MESHD in utero (OR=25.9 [2.2-305]) and admission in neonatal intensive care unit admission (OR=13.4 [3.0-60]), appeared higher than the controls. No maternal deaths were recorded.ConclusionsOur data suggest that under breastfeeding conditions with rigorous hygiene precautions and parental education, the risk of vertical transmission of the SARS-COV-2 virus is unlikely.

    Analysis of Management Approach to Newborn Care of Infants Delivered to COVID-19 MESHD Positive Mothers at Five Tertiary Care Centers in the UAE over a 7 Month Period 

    Authors: Monika Kaushal; Yamuna Tulasi; Ayush Kaushal; Aditya Rakhecha; Rafiq Memon; Karvendhan Ramasamy; Shoaib Khan

    doi:10.21203/ Date: 2021-01-10 Source: ResearchSquare

    ObjectivesTo assess newborn care practices, clinical characters and risks of mother to child transmission during rooming in and breastfeeding in infants born to mothers with COVID-19 MESHD.DesignRetrospective observational study.Participants5 Tertiary care centers located in the UAE. Infants born to mothers diagnosed with COVID-19 MESHD at the time of delivery, born between April 1st and October 30th 2020.MethodsIn this retrospective observational study, we analyzed the newborn care practices in various tertiary care hospitals and the rate of transmission of SARS-CoV-2 from mother to infant (vertical or horizontal) while rooming in, breastfeeding and post discharge. Results40 infants were born to mothers with COVID-19 MESHD at the time of delivery. One infant tested positive for S ARS-CoV-2 MESHDafter birth and had respiratory symptoms and f ever. MESHD 23 of the well infants were roomed in during their hospital stay and were breastfed. In 8 cases, the mother and baby were separated and isolated from the time of birth till discharge. 95% of the discharged infants were rooming in with mothers, 45% of the infants were exclusively breastfed and 55% were on mixed feeding (b reast milk MESHDand formula milk) at the follow-up. None of the infants developed significant health issues or symptoms attributable to SARS-CoV-2.ConclusionThe risk of mother to infant transmission of COVID-19 MESHD in the perinatal period is very low. Our study reaffirms the AAP guidelines that rooming in and breastfeeding of newborns born to COVID-19 MESHD positive mothers is safe without an increased risk of transmission by following mandated safety precautions. 

    Persistence and baseline determinants of seropositivity in health care workers up to nine months after COVID-19 MESHD

    Authors: Carlota Dobaño; Anna Ramirez; Selena Alonso; Josep Vidal-Alaball; Gemma Ruiz-Olalla; Marta Vidal; Rocio Rubio; Emma Cascant; Daniel Parras; Natalia Rodrigo Melero; Pau Serra; Carlo Carolis; Pere Santamaria; Anna Forcada; Jacobo Mendioroz; Ruth Aguilar; Gemma Moncunill; Anna Ruiz-Comellas

    doi:10.21203/ Date: 2021-01-07 Source: ResearchSquare

    We determined the duration and baseline determinants of antibody responses to SARS-CoV-2 up to nine months after COVID-19 MESHD symptoms onset in 173 primary health care worker patients from Spain. Seropositivity to SARS-CoV-2 spike MESHD SARS-CoV-2 spike PROTEIN and RBD antigens was 92.49% (60.69% IgM, 76.3% IgA, 90.17% IgG), with four suspected reinfection cases. Antibody levels significantly correlated with fever MESHD, hospitalization, anosmia/hypogeusia MESHD, allergies MESHD, smoking and occupation, and persisted 149-270 days in this cohort of patients

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.